B
Bull
Bull · 25%TAK
$18.07
Scenario price
$20.240
-0.119 (-0.59%)At close
Loading chart…
- High
- 20.390
- Open
- 20.280
- VWAP
- 20.27
- Volume
- 2.10M
- Mkt Cap
- 40.51B
- Low
- 20.170
- Amount
- 42.54M
- EV/EBITDA, TTM
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
AI analysis of Takeda Pharmaceutical Co Ltd (TAK)
BuyTakeda Pharmaceutical Co Ltd is a good buy right now due to its current price of 20.24, a strong year-to-date change of +29.58%, and an RSI of 75.75 indicating bullish momentum. The upcoming earnings date on October 29, 2026, with an EPS estimate of 0.31, adds to the potential for positive price movement. However, the main risk is the recent net income fluctuations, with a significant loss of -368.47 billion JPY reported in Q4 2026.
Valuation Metrics
The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) is 11.47, compared to its 5-year average forward P/E of 25.19.
Alphio AI Price Scenarios for TAK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.010-23NewsfilterArcotatug Tavatecan Shows Promising Results in Advanced Gastric Cancer Study
- 2.010-19Newsfilter
ENTYVIO Treatment Shows Significant Efficacy in UC Patients
- 5.010-15Newsfilter
ORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
TAK FAQ — answered by Alphio AI
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd is a good buy right now due to its current price of 20.24, a strong year-to-date change of +29.58%, and an RSI of 75.75 indicating bullish momentum. The upcoming earnings date on October 29, 2026, with an EPS estimate of 0.31, adds to the potential for positive price movement. However, the main risk is the recent net income fluctuations, with a significant loss of -368.47 billion JPY reported in Q4 2026.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.